Patients with controlled psoriasis still face systemic inflammation, cardiometabolic risks
A study co-authored by Joel M. Gelfand of the Perelman School of Medicine finds that residual inflammation persists among patients with psoriasis despite optimal disease response to biologic therapies, putting them at risk for broader health conditions.